214 related articles for article (PubMed ID: 16158059)
1. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
[TBL] [Abstract][Full Text] [Related]
2. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
Jung JH; Pendergast AM; Zipfel PA; Traugh JA
Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
6. An intramolecular SH3-domain interaction regulates c-Abl activity.
Barilá D; Superti-Furga G
Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
[TBL] [Abstract][Full Text] [Related]
7. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
Van Etten RA; Debnath J; Zhou H; Casasnovas JM
Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
[TBL] [Abstract][Full Text] [Related]
8. The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells.
Ogawa S; Toyoshima H; Kozutsumi H; Hagiwara K; Sakai R; Tanaka T; Hirano N; Mano H; Yazaki Y; Hirai H
Oncogene; 1994 Jun; 9(6):1669-78. PubMed ID: 8183562
[TBL] [Abstract][Full Text] [Related]
9. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.
Sriram G; Reichman C; Tunceroglu A; Kaushal N; Saleh T; Machida K; Mayer B; Ge Q; Li J; Hornbeck P; Kalodimos CG; Birge RB
Oncogene; 2011 Nov; 30(46):4645-55. PubMed ID: 21602891
[TBL] [Abstract][Full Text] [Related]
11. CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins.
Prosser S; Sorokina E; Pratt P; Sorokin A
Oncogene; 2003 Jul; 22(31):4799-806. PubMed ID: 12894221
[TBL] [Abstract][Full Text] [Related]
12. Examining the specificity of Src homology 3 domain--ligand interactions with alkaline phosphatase fusion proteins.
Yamabhai M; Kay BK
Anal Biochem; 1997 Apr; 247(1):143-51. PubMed ID: 9126384
[TBL] [Abstract][Full Text] [Related]
13. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.
Donaldson LW; Gish G; Pawson T; Kay LE; Forman-Kay JD
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14053-8. PubMed ID: 12384576
[TBL] [Abstract][Full Text] [Related]
14. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro.
Plath K; Engel K; Schwedersky G; Gaestel M
Biochem Biophys Res Commun; 1994 Sep; 203(2):1188-94. PubMed ID: 8093038
[TBL] [Abstract][Full Text] [Related]
16. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
Miyazaki K; Senga T; Matsuda S; Tanaka M; Machida K; Takenouchi Y; Nimura Y; Hamaguchi M
Biochem Biophys Res Commun; 1999 Oct; 263(3):759-64. PubMed ID: 10512753
[TBL] [Abstract][Full Text] [Related]
17. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.
Pisabarro MT; Serrano L
Biochemistry; 1996 Aug; 35(33):10634-40. PubMed ID: 8718852
[TBL] [Abstract][Full Text] [Related]
18. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
19. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
Mysliwiec T; Perego R; Kruh GD
Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
[TBL] [Abstract][Full Text] [Related]
20. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.
Ren R; Ye ZS; Baltimore D
Genes Dev; 1994 Apr; 8(7):783-95. PubMed ID: 7926767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
